Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Right. So it's NOT "FDA approved."
So what DO you know about the laws & permitting of medical marijuana facilities, dispensaries, & clinics in Pennsylvania then?
If you don't know anything about the subject maybe you shouldn't say anything. The same goes for the CEO making claims that simply aren't true.
Since when is Cannophen FDA approved? Show the proof please.
I have watched it. Other than talk, where's the proof? Where are the filings & applications? Because they are a matter of public record and just aren't there.
Why doesn't the name of their company (companies) or any of their officers appear on the public record of logged dispensary applications, dispensary permits pending, clinical or testing laboratories approved or pending, licensed clinical referral agents pending or approved, licensed producer/processor filing or applications?
I live in Pennsylvania and I am actively involved in the medical marijuana advocacy & law groups, so don't try pulling this fast & loose talk with me.
Show us the proof.
Come on now let's get real....there is ONE product on Amazon with 18 reviews, and Cannophen is likely to be a retail CBD product (meaning derived from hemp not marijuana). There are already TONS of such CBD quick buck products everywhere, I have even seen them in some gas station convenience stores.
The day this company puts out a product that is ACTUALLY a MARIJUANA PRODUCT or a cannabis derived CBD product, then maybe eventually there will be revenues.
BUT don't look for profits until:
1. PAOG asset acquisition costs are recouped (we don't even know what the assets are)
2. building a laboratory in Ohio construction costs are recouped
3. the cost of hiring, "training", and paying their chemist in Florida is recouped
4. cost of buying & remodeling Pittsburgh "facility" is recouped
5. cost of hiring a "professional PR firm" are recouped
6. cost of hiring a professional firm "to become a fully audited & reporting company" are recouped
7. cost of testing ginger menthol pain cream with ABICH are recouped (TSW on sale nowhere currently)
8. cost of peptide scar serum production are recouped (currently only for sale on Amazon)
9. costs of establishing a new business entity in Canada are recouped
10. I don't even what to say about the costs they are implying with whatever Cannophen actually is are recouped
11. the costs of their trips to California, Arizona, Ohio, Pennsylvania etc to "seek licensing" are recouped
Am I forgetting anything the company has told us they are doing ???
I'm a doubter but not a dummy....when this hits the 3's I'm jumping back in for a flip.
What assets exactly? Where did you find an accounting of their assets? Thank you in advance.
I suppose you are right. Expecting these companies to actually present full accounting is ridiculous and requires me to change my attitude.
I'd also like to see a full accounting of PAOG assets...I mean what are their actual ASSETS???? Do they OWN anything??? They probably just lease buildings (although claim to have bought one in Pittsburgh). And just how much money is on their books?
LOTS of questions before I would call this "good news."
The Sessions news would be great for RBII if they actually had any marijuana products, but they don't.
HUGE NEWS! And here we are back at .005 !!!
My greatest hope is this company makes me look incredibly stupid for doubting every day ha!!!!
Again, doesn't matter here...RBII doesn't have any marijuana products.
Why keep posting the same old PRs? No news about any actual marijuana products which is what investors are seeking. I'm going to assume their CBD products "in development" are hemp derived and not cannabis derived until they come to market in actual marijuana dispensaries as such to prove me wrong. OLD NEWS.
I'm ready for NEW news. I'd LOVE to be proved wrong.
Well one thing is for sure, you don't have to worry about them selling pot, because they don't have ANY marijuana products for sale. But yes, as far as taking massive share position and playing it as a flip everytime it bumps fractionally.....it's like clockwork.
Great, but RBII doesn't have any marijuana products. And I would bet their CBD products "in development" are just hemp derived. RBII is looking less and less like an actual play on marijuana speculation every day as investors wise up.
Back in the .004's !
My prediction for the next PR (whenever that may be)....
They get a mailing address in Canada to ride the wave of that country's news.
They release some type of CBD product (from hemp).
STILL no marijuana products.
What's the point of calling ABICH? I don't think anyone is really interested in the test results of the vanity/retail pain creams containing ginger and menthol . Potential investors or current investors are waiting on MARIJUANA products the company has promised. The ABICH testing was not on any marijuana product. WHERE ARE THE THC/MARIJUANA PRODUCTS? Or am I wrong and investors are banking on a serum on Amazon with a whopping 18 reviews?
That's a broad answer, albeit in response to a broad criticism. But I disagree there are not ALWAYS delays in new medicines or technologies or products. Most legit companies work through or anticipate any sort of processing or production issues/delays/setbacks BEFORE announcing release target dates for their products. A release date for a company product isn't just some arbitrary day/date/time...it's a solid commitment to the market it seeks to supply.
Notice how all the recent talk is about CBD version of the pill? That's because they know they can dump out some quickie retail product with CBD in it (there are hundreds if not thousands of hemp CBD products legally available on the retail market) instead of delivering on promises of "contract with marijuana producers/processors" etc etc.
I would look for this to flirt with high 3's before it's pumped again.
I agree with you! Yes I am here to seek info and due more due diligence, as well as share information and opinions.
Thank you for your information on the chemist. Looking forward to news about the laboratory RBII was building in Ohio.
And for the record, asking legitimate questions seeking honest answers certainly does not qualify as sabotage or subterfuge in my opinion.
News in Ohio? Still waiting on news about the Ohio lab they were building that has an "in house chemist" they hired. It was previously stated by the company in January 2018 that the lab was "close to completion" and "fully operational."
I would think with such a huge investment it would take to build a lab and hire a chemist we would be hearing something by now. It will have a big impact on profits/revenues/forecast.
TSW Pain Cream IS A COSMETIC PRODUCT....
Investors take note, in the documents of the tests performed by ABiCh lab in Quebec presented in section 2.1 of the Study Design as "Aim of the Test" CLEARLY STATES (quote)
"The challenge test is a predictive method useful to evaluate the effectiveness of a preservation system used in the formulation of a COSMETIC PRODUCT."
AND in section 2.3 under "product description" CLEARLY STATES (quote)
"representing the protection capacity of a COSMETIC FORMULATION."
So the evidence & proof the company is supplying in print CLEARLY STATES THIS IS A COSMETIC PRODUCT.
Why are they (RBII) touting this in audio/press releases as medicine that "doctors can write a prescription for" when this is nothing more than another retail item for which there are VERY different FDA guidelines as opposed to prescription items???
Thank you Wall Street Kid & Hunchbackgeek for supplying proof the company is SAYING something very different about their products than what they are actually producing or testing. Good solid info.
Thank you.
So a compounding application as applies to the FD&C section with the FDA? That doesn't make any sense since RBII stated they are seeking NDC code ("so doctors can write prescriptions" via audio) and the FDA doesn't approve compounds under section 503 of the Drug Quality & Security Act revision.
So which is it with TSW? Is it seeking FDA approval for an NDC for prescriptions or is it a "compounded" mixture for FD&C/CGMP guidelines as a cosmetic product? Because it can't be both. You are stating one thing but the company has stated something very different in their PRs.
Thank you in advance for clarification.
NOT FDA APPROVED....
Can someone please provide more information regarding the FDA and TSW Pain Cream? The product does NOT appear in the FDA's database of approved products, or list of pending NDC products. I see in RBII's press release dated 10/10/2018 they have said the TSW Pain Cream received FDA "clearance." This wording is misleading.
Great answer, good job. My questions here are part of my due dilligence.
What does that mean "designed to treat opiate addiction" though? Is it a painkiller alternative? Does it reduce opiate withdrawal symptoms? Does it treat or block a specific receptor in the brain that will make a person no longer an addict? Where are you getting that information? Please post the press releases or company documents that states that specifically. It is irresponsible to throw around generic statements like that simply because "opiate addiction" are hot button buzzwords.
From what I've read & interpreted Cannophen is simply a branded means of oral delivery they are licensing. Cannaphen isn't actually one specific thing, or at least they certainly have not presented it as such. Everything they have stated conveys it is some sort of "metered dosing" system capsule. It would be up to whoever decides to license the name "Cannophen" for their oral product to decide what marijuana strain or ingredient will fill the capsule, and the desired result or effect will depend on those ingredients. This is NOT a pure "pharmaceutical" play as such, it is a licensing play....for instance "Cannophen for nausea treatment" or "Cannophen for anxiety cessation" etc. would each be different but licensed as "Cannophen brand." Common sense would dictate as such, because a strain you would use to help induce sleepiness would certainly not be the same as a strain that produce an alert/energetic effect.
If there IS a plan for Cannophen to be a SINGULAR strain or treatment for one specific ailment, the company has done NOTHING to present it as such. My gut tells me this pink sheet stock/shell company eventually will produce a hemp derived (not marijuana) CBD capsule called "Cannophen" so they can sell it online, claiming to help with everything that ails. There are HUNDREDS of such products on the market presently. Nothing special by any means.
If I have misinterpreted, blame the lack of specifics from the company. You are of course encouraged to dig through the press releases and come to your own conclusions.
ASKING AGAIN SINCE NO RESPONSE FROM IR....any news on status of building their laboratory/compounding facility with in-house chemist in Ohio? That will have a major effect on revenues/profits. It is not cheap to set up a laboratory or pay an "in-house chemist." RBII claimed it was "near completion late 2017." Mentioned again in the Feb. 2018 PR.....
"The Company has also recently hired a seasoned chemist who will serve as Chief Chemist in-house at the Company's Ohio Laboratory. COO Arthur Hall states, "Our Chief Chemist will be traveling to Florida to train with our staff there on overall procedures and protocol. We are thrilled to have secured talent at this level which will greatly expedite research and development on new product ideas as well as staff expertise in all of our locations."
Welcome to the world of shell companies & penny stocks! Play it as the flip it has proven to be time & again.
You should also add "no marijuana products on the market" to your points as well.
Agree. It's cooled off for retail trades/flippers sure, but as far as an investment it is an incredible time to view the long perspective.
If there is a bright side, it is years away. Next you will see buzz about the "CBD only" iteration of Cannophen. There are THOUSANDS of CBD products already on the market, with hemp derived CBD already legal and available for retail sale. I'm questioning whether this company will have any actual marijuana products EVER or if they are just playing close to the vest in the gray area of marketspeak to try to capture momentum.
There's no sustained "rally" because so far we are only seeing a lot of talk centered around what the rest of the sector is actually accomplishing and those news points, i.e. "Canada."
Potential investors need to realize as of this moment the sector is extremely active, but RBII has ZERO products containing THC or CBD available for sale in any state or country. They didn't in 2017 and the hot talk was it was all going to happen in 2018. Now 2018 is winding down and still no THC or CBD products, so the talk will swing to 2019.
Ohio lab status?
As this drops again, thinking of re-entering. Curious if anyone has information about RBII's Ohio laboratory & compounding facility they claimed was near completion in late 2017 that would have an in-house chemist is in fact operational or just more talk? This company's claims are all over the map and I'd like to see some solid info. NO response from investor relations direct contact.
There's the pop I was looking for. I have nearly doubled my money in a very short time, and FULL DISCLOSURE I HAVE SOLD/EXITED MY TOTAL POSITION in this one. It's basic math like I went on about yesterday. Not sure if I'll be back, this company has a long way to go and some very obvious red flags, but I'll keep watching. Good luck to all, proceed with caution.